Last mentioned: Mar 2, 2026
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
Reporting Season Pressure
Difficult February reports for CSL and Sonic Healthcare extend index declines.
Anteris Funding
Anteris Technologies raises approximately $440 million for heart valve technology.
Nasdaq Biotech Peak
The index records a 30% annual gain, diverging from broader tech markets.
Record Funding Year
Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
ASX Healthcare Slump
The sector begins a calendar year decline of 25% led by major heavyweights.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.